Acquisition of UK infection control company Medimark Scientific Limited

Byotrol plc, the AIM listed anti-microbial hygiene company, is pleased to announce the acquisition of Medimark Scientific Limited (“Medimark”) a leading provider of biocide-based infection control products into the animal and human healthcare markets.

Medimark is a profitable and growing business which has a broad sales, marketing and distribution expertise. Medimark sells infection control products used on surfaces, instruments and hands for the Animal Health, Human Health, Laboratory, Environment and Retail markets. The company is based in Sevenoaks, Kent, and is ISO9001 quality registered with supporting registration under the Medical Device Directive

There is an existing and long-standing relationship already in place between the two companies – Byotrol is currently a white label supplier of hand sanitisers to Medimark, which it sells under its Esense brand.

Highlights:

  • Immediately provides Byotrol with greater scale than could be achieved through current rates of organic growth. Medimark is profitable and cash generative and fits extremely well with Byotrol’s existing products and technology.
  • Highly complementary acquisition, offering extensive sales, marketing and distribution expertise in Byotrol’s core markets. Specific complementary with Byotrol’s Professional and Petcare businesses with significant synergies expected over time, including: enhanced distribution of Byotrol technologies to Medimark customers, in the UK and overseas, boosting economies of scale, distribution and market segment expertise, highly experienced, well-connected and resilient sales team and sales support and introduction of stronger disinfectant technologies to Byotrol portfolio including a proprietary sporicidal formulation
  • Doubles workforce, creating immediate critical mass with cost synergies available from bringing Medimark technical work in house.
  • Executive management staying with the combined business for the earnout and beyond, with incentives closely aligned with Byotrol shareholders.


Commenting on the
acquisition, John Langlands, Byotrol Chairman, said:

“We are delighted to have concluded the acquisition of Medimark and we welcome its directors, employees, customers and stakeholders to Byotrol. The fit between the two companies is remarkably strong with Medimark’s excellent sales and marketing capabilities dovetailing very well with our technical expertise. We also see more opportunities to take the combined group’s infection control products into consumer markets. Our enlarged operations will now be offering cutting-edge infection control products to more customers in our jointly-targeted markets with improved propositions. We have a strong balance sheet and are confident that the combination of the two companies will bring Byotrol to critical mass with the resources to deliver sustained growth and profitability.“


Rick Hayman, the MD and
major shareholder of Medimark, added:

“Joining forces with Byotrol is a very exciting step forward for the Medimark team, enabling us to take our business to a new level. With their technical expertise and our combined commercial and sales experience skills, we see the two companies as an excellent fit. We very much look forward to pursuing the market opportunities together with the Byotrol team.”

FOR MORE INFORMATION PLEASE CONTACT

PR@medi-mark.co.uk

Previous article